title: American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma & Immunology Omalizumab-Associated Anaphylaxis Joint Task Force follow-up report.
authors.forename: Linda
authors.initials: L
authors.lastname: Cox
authors.forename: Phillip
authors.initials: P
authors.lastname: Lieberman
authors.forename: Dana
authors.initials: D
authors.lastname: Wallace
authors.forename: F Estelle R
authors.initials: FE
authors.lastname: Simons
authors.forename: Ira
authors.initials: I
authors.lastname: Finegold
authors.forename: Thomas
authors.initials: T
authors.lastname: Platts-Mills
authors.forename: Lawrence
authors.initials: L
authors.lastname: Schwartz
mesh_terms: D026683:Advisory Committees; D000707:Anaphylaxis / Q000139:chemically induced* / Q000453:epidemiology*; D000888:Antibodies, Anti-Idiotypic / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D001249:Asthma / Q000188:drug therapy; D064420:Drug-Related Side Effects and Adverse Reactions; D006801:Humans; D000069444:Omalizumab
chemical_list: D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069444:Omalizumab